Fund Investments

We invest in venture capital funds and growth capital funds in order to access great investors at each stage of the capital and innovation cycle. We have made over 75 targeted investments in China-focused funds with top-tier managers and key sector exposure. A select sample is presented below.

 

VENTURE CAPITAL

Seed and early stage managers have played an impactful role in fueling dramatic innovation in China.

 

GROWTH CAPITAL

Growth Equity managers dominate in China capitalizing on broad economic expansion yesterday and today.

 

PRIVATE EQUITY

Larger, late stage investors offer significant opportunities as market leaders prepare for M&A and IPO transactions.

Direct Investments

Sagamore seeks direct investment opportunities in line with China's consumption upgrade, looking at sectors including fintech, healthcare, artificial intelligence, and education.

ASLAN PHARMACEUTICALS

ASLAN PHARMACEUTICALS

Oncology and inflammation drug discovery company based in Singapore, Taipei and Shanghai

ASLAN PHARMACEUTICALS
Sagamore was a founding investor in ASLAN in 2010, leading the Series A investment alongside its affiliate fund BV Healthcare. ASLAN listed in Taipei in 2017.
GRASSLAND</br> FINANCE

GRASSLAND
FINANCE

Hong Kong-based financial services holding company serving the micro, small and medium-sized enterprises (MSMEs) in China

GRASSLAND</br> FINANCE
From an initial investment in 2013 in the profitable operations in Chifeng, Inner Mongolia started by Accion International in 2009, Grassland now operates in Wanzhou, Chongqing as well and has pending licenses in Hunan and Pudong. Sagamore is the largest shareholder and is targeting an IPO in 2019.
MOMENTA

MOMENTA

One of China’s leading autonomous driving startups, offering multi-level solutions as well as big data services.

MOMENTA
Momenta, established in 2016, is one of the leading autonomous driving companies in the world. Momenta is building the “brains” for autonomous vehicles. Their deep-learning based software in perception, HD semantic mapping, and data-driven path planning enables the realization of full autonomy.
WUXI </BR> APPTEC

WUXI
APPTEC

WuXi AppTec provides R&D and manufacturing services that enable life sciences companies worldwide to advance discoveries and deliver groundbreaking treatments to patients.

WUXI </BR> APPTEC
Established in December 2000, WuXi AppTec has industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices. Sagamore participated in the landmark take-private transaction in 2015.
NEAT

NEAT

Neat aims to offer more streamlined banking and financial management products than traditional banks

NEAT
The company's platform combines biometrics, machine learning and artificial intelligence to offer digital banking services which includes cross-border payments, a debit card and digital wallet, enabling users to manage their expenses and budgets digitally. Sagamore invested in 2018.
XIAOMI

XIAOMI

Largest smartphone distributer in China that designs, develops and sells phones, mobile apps and consumer electronics

XIAOMI
Sagamore invested in one of the firm's venture financing rounds alongside DST, GIC, Hopu and Yunfeng.

History

Sagamore's founders have worked together since 2002 and have invested in over 100 funds and companies in Asia and the US. Sagamore's first investments focused on biotechnology and expanded to fund and direct investments in China with Sagamore China Partners I (SCP I) in 2006. The team raised subsequent funds SCP II (2010), SCP III (2013), SCP IV (2016) and SCP V (2018). In total, Sagamore has over $500m in assets under management for investing in opportunities in China.

2002
Firm Established
2006
Sagamore China Partners I
2010
Sagamore China Partners II
2013
Sagamore China Partners III
2016
Sagamore China Partners IV
2018
Sagamore China Partners V

Team

Led by seasoned entrepreneurs, founders Peter Brooks and Rodrigo Yang, the firm's seven investment professionals are based in Beijing (sourcing and diligence) and Hong Kong (investment analytics).

Rodrigo Yang
Peter Moody Brooks
Jing Wang
Edward Cumberlege
Virgil Chan
Emmanuel Hui
Chelsea Lin
Henry Mattinson

Contact

Sagamore has offices in Beijing and Hong Kong. We are always looking for exciting business opportunities and new talent to join our team. Please contact us for more information.

 

Beijing

Room 901, Block F,
Phoenix Place, Tower 21,
No. A5 Shuguangxili, Chaoyang District,
Beijing, 100028

 

Hong Kong

Level 6, Champion Tower,
3 Garden Road,Central,
Hong Kong